Payment overview · 2025
General Payments
$1,208.63
42 reported records · 16 companies
Healthcare provider profile · identity verified
Henry Dewitt Rodeffer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FERNANDINA BEACH, FL · NPI 1710978077
Verified facts
What the public records show
CMS Open Payments records show Henry Dewitt Rodeffer, M.D. received $1,208.63 in general payments during 2025 across 42 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $377.68 | 31.2% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $137.74 | 11.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.67 | 10.9% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.66 | 8.1% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.79 | 7.8% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $68.97 | 5.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.96 | 5.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $62.86 | 5.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.67 | 3.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.64 | 2.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.04 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.21 | 1.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.10 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.87 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.72 | 1.4% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $15.05 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,208.63 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $211.25 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $166.43 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $137.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $94.79 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.53 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $68.97 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $62.86 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.62 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $40.67 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.80 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $11.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 71 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1086 | 324 |
| Levothyroxine Sodium | Levothyroxine Sodium | 626 | 177 |
| Atorvastatin Calcium | Atorvastatin Calcium | 575 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 499 | 148 |
| Losartan Potassium | Losartan Potassium | 462 | 134 |
| Famotidine | Famotidine | 357 | 117 |
| Trazodone Hcl | Trazodone Hcl | 352 | 102 |
| Lisinopril | Lisinopril | 347 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 344 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 72 |
| Gabapentin | Gabapentin | 245 | 71 |
| Metformin Hcl | Metformin Hcl | 215 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 209 | 63 |
| Ezetimibe | Ezetimibe | 208 | 57 |
| Omeprazole | Omeprazole | 202 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 61 |
| Sertraline Hcl | Sertraline Hcl | 159 | 51 |
| Eliquis | Apixaban | 153 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 142 | 49 |
| Tramadol Hcl | Tramadol Hcl | 139 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 38 |
| Alprazolam | Alprazolam | 127 | 42 |
| Furosemide | Furosemide | 122 | 48 |
| Metformin Hcl Er | Metformin Hcl | 122 | 41 |
| Jardiance | Empagliflozin | 121 | 32 |
| Montelukast Sodium | Montelukast Sodium | 120 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 34 |
| Ozempic | Semaglutide | 109 | 19 |
| Celecoxib | Celecoxib | 106 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 29 |
| Bupropion Xl | Bupropion Hcl | 98 | 26 |
| Carvedilol | Carvedilol | 96 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 39 |
| Allopurinol | Allopurinol | 87 | 21 |
| Synthroid | Levothyroxine Sodium | 81 | 19 |
| Meloxicam | Meloxicam | 71 | 28 |
| Mounjaro | Tirzepatide | 71 | 16 |
| Potassium Chloride | Potassium Chloride | 70 | 25 |
| Atenolol | Atenolol | 68 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 24 |
| Simvastatin | Simvastatin | 61 | 20 |
| Farxiga | Dapagliflozin Propanediol | 60 | 15 |
| Dutasteride | Dutasteride | 58 | 21 |
| Alendronate Sodium | Alendronate Sodium | 57 | 20 |
| Donepezil Hcl | Donepezil Hcl | 56 | 11 |
| Xarelto | Rivaroxaban | 55 | 14 |
| Temazepam | Temazepam | 54 | suppressed |
| Folic Acid | Folic Acid | 51 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Fenofibrate | Fenofibrate | 50 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 17 |
| Trulicity | Dulaglutide | 49 | suppressed |
| Valsartan | Valsartan | 49 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 43 |
| Amoxicillin | Amoxicillin | 46 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 15 |
| Finasteride | Finasteride | 46 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Myrbetriq | Mirabegron | 43 | 11 |
| Estradiol | Estradiol | 42 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 14 |
| Prednisone | Prednisone | 40 | 24 |
| Clonidine Hcl | Clonidine Hcl | 38 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Valacyclovir | Valacyclovir Hcl | 37 | 13 |
| Rybelsus | Semaglutide | 36 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 35 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 12 |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 14 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Clonidine | Clonidine | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Febuxostat | Febuxostat | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,208.63 · 42 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, FARXIGA, FREESTYLE LIBRE 3, FUROSCIX, GEMTESA, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, SHINGRIX, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error